**Name of Journal: *World Journal of Diabetes***

**Manuscript NO: 38909**

**Manuscript Type: ORIGINAL ARTICLE**

***Case Control Study***

**Association of *TCF7L2* mutation and atypical diabetes in a Uruguayan population**

Beloso C *et al*. TCF7L2 in atypical diabetes

Carolina Beloso, Jorge Souto, Matias Fábregat, Gerardo Romanelli, Gerardo Javiel, Adriana Mimbacas

**Carolina Beloso, Adriana Mimbacas,** Biodiversity and Genetics Department, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo 11600, Uruguay

**Jorge Souto,** Cytogenetics Laboratory, Hematology and Transplant Service of Hematopoietic Progenitors, Maciel Hospital, ASSE, Montevideo 11600, Uruguay

**Jorge Souto,** Department of Genetics, Faculty of Medicine, UDELAR, Montevideo 11800, Uruguay

**Matias Fábregat,** Human Molecular Genetics Laboratory, Institut Pasteur de Montevideo 11400, Uruguay

**Gerardo Romanelli,** Cell Signaling and Nanobiology Laboratory, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo 11600, Uruguay

**Gerardo Javiel,** Unit of Diabetes Hospital Pasteur, ASSE-Ministry of Public Health, Montevideo 11400, Uruguay

**Gerardo Javiel,** Diabetologyc Service of Private Health Center, Centro de Asistencia del Sindicato Médico del Uruguay, Montevideo 11600, Uruguay

**ORCID number:** Carolina Beloso (0000-0003-4469-5572); Jorge Souto (0000-0002-3676-1712); Matias Fábregat (0000-0002-8248-5464); Gerardo Romanelli (0000-0002-4870-5320); Gerardo Javiel (0000-0002-5931-2055); Adriana Mimbacas (0000-0001-5302-619X).

**Author contributions:** Beloso C processed the samples from the atypical diabetes patients and controls, performed analysis and interpretation of the data, and participated in writing of the manuscript; Souto J contributed to laboratory processing of the samples and writing of the manuscript; Fábregat M acquired the patients’ data and performed processing of the “classical” diabetes samples; Romanelli G contributed to the statistical analyses; Javiel G selected the patients for the protocol and attended to them in clinic, and made critical revisions related to the important intellectual content of the manuscript; Mimbacas A made substantial contributions to the conception and design of the study and critical revisions related to the important intellectual content of the manuscript, and gave final approval of the version of the article to be published.

**Institutional review board statement:** The study was approved by the Ethics Committees of each of the participating institutions (Law 18331).

**Informed consent statement:** All patients provided written informed consent.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest concerning this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Adriana Mimbacas, PhD, Assistant Professor,** Biodiversity and Genetics Department, Instituto de Investigaciones Biológicas Clemente Estable, Avenida Italia 3318, Montevideo 11600, Uruguay. amimbacas@iibce.edu.uy

**Telephone:** +598-2-4861417

**Fax:** +598-2-4875548

**Received:** March 22, 2018

**Peer-review started:** March 22, 2018

**First decision:** May 16, 2018

**Revised:** June 6, 2018

**Accepted:**July 10, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To investigate if mutations in *TCF7L2* are associated with “atypical diabetes” in the Uruguayan population.

***METHODS***

Healthy, nondiabetic controls (*n* = 133) and patients with type 2 diabetes (*n* = 177) were selected from among the presenting population at level-3 referral healthcare centers in Uruguay. Patients with type 2 diabetes were subgrouped according to “atypical diabetes” (*n* = 92) and “classical diabetes” (*n* = 85). Genotyping for the rs12255372 and rs7903146 single nucleotide polymorphisms (SNPs) in the *TCFTL2* gene was carried out with *Taq*Man® probes. Random samples were sequenced by Macrogen Ltd. (South Korea). Statistical analysis of the SNP data was carried out with the SNPStats online tool (http://bioinfo.iconcologia.net/SNPstats). The best inheritance model was chosen according to the lowest values of Akaike’s information criterion and Bayesian information criterion. Differences between groups were determined by unpaired *t*-tests after checking the normal distribution or were converted to normalize the data. The association of SNPs was tested for matched case-control samples by using χ2 analysis and calculation of odds ratios (ORs) with 95% confidence intervals (CIs). All statistical tests were performed using SPSS v10.0 and EpiInfo7 statistical packages. Significant statistical differences were assumed in all cases showing adjusted *P* < 0.05.

***RESULTS***

We genotyped two *TCF7L2* SNPs (rs7903146 and rs12255372) in a population-based sample of 310 Uruguayan subjects, including 133 healthy control subjects and 177 clinical diagnosed with type 2 diabetes. For both SNPs analyzed, the best model was the dominant type: rs12255372 = G/G *vs* G/T+T/T, OR = 0.63, 95%CI: 0.40-0.98, *P* < 0.05 and rs7903146 = C/C *vs* C/T+T/T, OR = 0.79, 95%CI: 0.41-1.55, *P* = 0.3. The rs12255372 SNP showed high association with the type 2 diabetes cases (OR = 1.60, 95%CI: 1.20-2.51, *P* < 0.05). However, when the type 2 diabetics group was analyzed according to the atypical and classical subgroupings, the association with diabetes existed only for rs12255372 and the classical subgroup (*vs* controls: OR = 2.1, 95%CI: 1.21-3.75, *P* < 0.05); no significant differences were found for either SNP or atypical diabetes.

***CONCLUSION***

This is the first time SNPs\_*TCF7L2* were genotyped in a diabetic population stratified by genotype instead of phenotype. Classical and atypical patients showed statistical differences.

**Key words:** TCF7L2; Atypical diabetes; Type 2 diabetes; Latin America; TaqMan

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This is the first time single nucleotide polymorphisms (SNPs) of the *TCF7L2* gene were genotyped and comparatively assessed in Uruguayan type 2 diabetes patients with ”atypical” and “classical” cases. The results show that these two populations are genotypically different. The only statistical association found involved one of the SNPs, rs12255372, and classical diabetes. No association was found to exist between either of the two SNPs examined (rs7903146 and rs12255372) and atypical diabetes. The findings in this study confirm the results of our previous investigations, which indicated that atypical and classical diabetes are two separate entities of the diabetes disease.

Beloso C, Souto J, Fábregat M, Romanelli G, Javiel G, Mimbacas A. Association of *TCF7L2* mutation and atypical diabetes in a Uruguayan population. *World J Diabetes* 2018; In press

**INTRODUCTION**

Diabetes mellitus is a global public health problem, and the Uruguayan population poses no exception. The prevalence of diabetes in Uruguay is 8%[1], accounting for 3.3 million of the country’s inhabitants[2]. Worldwide, type 2 diabetes (T2D) is the most common form, with incidence and prevalence having reached epidemic proportions.

Since 2009, our group has published on patients that were difficult to classify from a clinical point of view because they did not present a correlation between phenotype and genotype[3–5]. The current international guidelines for defining the type of diabetes present in an individual are still not sufficient to diagnose atypical diabetes. Patients with atypical diabetes do not fit exactly in any of the groups defined in the guidelines because they do not precisely follow the classical presentation and disease evolution and they show poor therapeutic response.

These patients have been treated in level-3 healthcare settings. The atypical cases could be bypassed inadvertently by healthcare providers if the appropriate genetic and immunological analyses are not carried out, primarily because overweight or obese status is a gross indictor of insulin-resistance. Indeed, these visibly assessed features are the primary disorder considered in classification of type 2 diabetes in the internationally used recommendations of the American Diabetes Association (ADA)[6]. Atypical diabetes could be a confounder in latent autoimmune diabetes of adults (LADA) but the two are distinguishable according to several specific clues. LADA includes (1) patient onset at ≥ 30 years of age (we have found children and young people with atypical diabetes); (2) an absence of metabolic syndrome along with features of obesity, high blood pressure and high cholesterol levels (all of the atypical patients we have encountered have this condition); and (3) uncontrolled hyperglycemia despite using oral agents; and d) other autoimmune diseases (with clinical evidence for diagnosis) that are not necessarily present in atypical diabetes (*i.e*., Graves' disease and anemia)[7].

For the work presented herein, we analyzed the association of transcription factor 7-like 2 (*TCF7L2*), one of the major genes related to T2D, continuing with the genetic characterization of atypical diabetes patients. Our choice of this gene was based upon the remarkable amount of research that has been carried out to date on the genetic factors of diabetes, and from which *TCF7L2* has emerged as one of the strongest T2D susceptibility genes[8–10].

TCF7L2 is a Wnt signaling-associated transcription factor, expressed in the intestine, pancreas, others tissues and plays an important role in the -cell proliferation and insulin secretion[11]. Publications reviewing the possible mechanisms have led to several theories on the processes by which altered TCF7L2 production or function may cause diabetes. Among these, reduced insulinotropic effect of incretin hormones, of GLP-1 signaling in -cells especially, impaired insulin processing or release, and decreased -cell mass seem to be the most probable etiological mechanisms[12–15]. The fact that genes encoding Wnt signaling pathway factors are active in cells or the indication that they may be involved in insulin secretion supports the notion that cell dysfunction is a crucial final step on the path to diabetes[16].

The *TCF7L2* gene is located on chromosome 10q25 and is composed of two major domains: a catenin-binding domain (exon 1) and a central DNA-binding HMG domain (exons 10 and 11). Variations in this gene have been consistently associated with T2D in studies of different populations, namely those of Caucasian, Asian and African origin, and specifically involving two intronic single nucleotide polymorphisms (SNPs): rs12255372 (G>T) and rs7903146 (C>T)[17–25]. For rs12255372, homozygous carriers of the rare T allele produce 2.5-fold higher levels of *TCF7L2* transcript than wild-type carriers, while heterozygous carriers of both alleles produce 1.5-fold higher[26]. This SNP in particular affects diabetes through deficiency in insulin secretion, more so than through insulin resistance[14].

For rs7903146, it is more associated with capacity of insulin secretion than insulin resistance of the -cell[27]. The allele T carriers permit the decrease of insulin secretion in postprandial state. This is an important characteristic becuse it is possible messure the cell response to glucose, aminoacid and incretins[28].

In this study, we investigated the association between the *TCF7L2* SNPs rs1255372 and rs7903146 in a control (nondiabetic) group and a case (diabetic) group consisting of patients with classical or atypical T2D in the Uruguayan population. This study represents the first time these SNPs have been investigated by stratifying the study population according to presence or absence of HLA and nonHLA susceptibility genes to T2D in patients with body mass index (BMI) ≥ 25 kg/m2.

**MATERIALS AND METHODS**

We analyzed a total study population of 310 individuals, including T2D patients (*n* = 177) and controls (*n* = 133) that were enrolled in the study between 2004 and 2012. Recruitment of patients was done by selecting from two referral diabetes healthcare centers in Montevideo, Uruguay, namely the Pasteur Hospital and CASMU-IAMPP.

The study was performed in accordance with the Declaration of Helsinki of the World Medical Association and was approved by the Ethics Committees of both participant institutions (Law 18331). All cases and controls signed an informed consent form for participation in this investigation.

***T2D patients***

Patients were selected according to ADA recommendations[6]. We took into consideration another criterion, that being patients who had received a multidisciplinary care approach for their diabetes, showed good adherence to their treatment regimen (including a nutritional and physical activity plan according to their functional capabilities), and had received one or more oral antihyperglycemic drugs.

For the stratification of T2D patients into the classical and atypical diabetes groupings, we used the same classification standards as in our previous studies[3–5]. For atypical diabetes, 92 of the patients met the following inclusion criteria: (1) BMI ≥ 25 kg/m2 and categorization following the World Health Organization overweight and obesity guidelines (25-29.9 kg/m2 and ≥ 30 kg/m2 respectively); (2) having reached the education and nutrition plans’ objectives as per international guidelines; (3) having presented doubts about their disease classification and/or not having reached a good therapeutic response (*i.e.* no decrease of 1.5% in HbA1c levels shown in two consecutive measurements after 3 mo[29]); and (4) presence of autoimmune-diabetes-susceptibility HLA alleles (the HLA DQB1\* 0201-0302 and DR 3-4 susceptibility alleles were considered for the Uruguayan population[30]). For classical diabetes, 85 patients fulfilled the (1) and (2) inclusion criteria listed above but did not present doubts about their diagnosis and did not show presence of autoimmune-susceptible genes.

Individuals who fit the inclusion criteria but had other metabolic disorders or were undergoing tumor processes were excluded from this study.

***Control (healthy, nondiabetic) subjects***

One hundred and thirty-three healthy, nondiabetic subjects were recruited from among blood donors at the Hemotherapy Department of Pasteur Hospital between 2014 and 2015. The blood donors presented for this service on a volunteer basis. Prior to the sample extraction, the attending doctors carried out an exhaustive questionnaire survey of each donor, which included information on chronic or infectious diseases and taking of any medication(s). Blood pressure was taken and weight and height were recorded in order to calculate the BMI (kg/m2). Laboratory tests were carried out and individuals with infectious diseases such as human immunodeficiency virus and hepatitis A/B/C were excluded from enrollment. At the time of sample extraction, none of the donors had diabetes, but this did not rule out the possibility that they could have developed it in the future since it is a multifactorial disease. The majority of the population that donates blood has an average age of approximately 38 years.

Of the 300 individuals that were initially included as the control population, we selected those who had a BMI similar to that of the sample of patients with atypical diabetes in order to avoid a confounding variable. In addition, we had already shown in a previous study that this variable does not have a statistically significant difference between classic and atypical diabetes cases[5].

***Genetic typification***

DNA was obtained from peripheral blood using the standard phenol/chloroform technique. The rs12255372 (G>T) and rs7903146 (C>T) SNPs in the*TCFTL2* gene were genotyped using *Taq*Man® Probes for real-time PCR in the Rotor-GeneTM 6000 PCR machine (Corbett Research, Sydney, Australia). The primers and probes for SNP rs12255372 were designed with the Primer3Plus software (Boston, MA, United States) and AlleleID® software (Palo Alto, CA, United States), respectively. The primer sequences were as follows: forward, TCTGGCTTGGAAAGTGTA; reverse, GAGGCCTGAGTAATTATCAGAA. The probe sequence was as follows: FAM/HEX-CCAGGAATATCCAGGCAAGAAT[T/G]ACCA-BHQ1. The rs7903146 primers and probe were obtained from the catalog of genotyping experiments in *Taq*Man® SNP Genotyping Assays (Life TechnologiesTM, Carlsbad, CA, United States). The primer sequences were as follows: forward, GCCTCAAAACCTAGCACAGC; reverse, GTGAAGTGCCCAAGCTTCTC. The probe sequence was as follows: VIC/HEX TAGAGAGCTAAGCACTTTTTAGATA[C/T]TATATAATTTAATTGCCGTATGAGG. In both cases, a commercial genotyping kit (Platinum® Quantitative PCR SuperMix-UDG); InvitrogenTM by Life TechnologiesTM) was used for the genotyping procedure.

Melting curve analyses were performed using the Rotor-GeneTM 6000 software v.1.7 (build 75) and the accompanying algorithm. Random samples were sequenced by Macrogen Ltd. (Seoul, South Korea) and were aligned using MEGA4 (Molecular Evolutionary Genetics Analysis software, Tempe, AZ, United States).

***Statistical analysis***

The statistical analyses for the polymorphisms were done with the online tool for SNP analysis, SNPStats (https://www.snpstats.net/start.htm?http://bioinfo.iconcologia.net/SNPstats). The best inheritance model was chosen according to the lowest values of Akaike’s information criterion (AIC) and Bayesian information criterion (BIC). Continuous variables were expressed as means and standard deviations. Differences between groups were determined by unpaired *t*-tests after verification of normal distribution, or converted to normalize the data.

The association of SNPs in matched case-control samples was tested using 2 analysis and calculation of odds ratios (ORs) with 95% confidence intervals (CIs). All tests were performed using the SPSS statistics package version 22 (IBM Corp., Armonk, NY, United States) and Epi Info™ statistics package version 7 (Atlanta, GA, United States). Significant statistical differences were assumed in all cases having adjusted *P* < 0.05.

**RESULTS**

We genotyped two *TCF7L2*SNPs-rs7903146 and rs12255372-in a population-based sample of 310 Uruguayan subjects, including 133 control subjects and 177 patients clinically diagnosed with T2D. The most relevant anthropometric values for the T2D and control groups are presented in Table 1. The T2D atypical and classical subgroups are presented in Table 2, showing the main clinical characteristics of each.

The best inheritance model was the dominant model for both SNPs analyzed: rs12255372= G/G *vs* G/T+T/T, AIC = 423.4, BIC = 430.8; and rs7903146 = C/C *vs* C/T+T/T, AIC = 426.4, BIC = 433.9. The rs12255372 SNP was the only variation that showed high association with the disease (Table 3). Comparative statistical analysis of the atypical and classical diabetes subgroups showed association only between the classical diabetes *versus* controls for rs12255372 (Table 4).

**DISCUSSION**

Diabetes mellitus is a complex disease, in which genetic and environmental factors are interweaved. After the discovery of *TCF7L2* as a key player in T2D etiology, several works in multiethnic populations identified two main SNPs in this gene, rs12255372 and rs7903146, and characterized them as the most relevantly associated to T2D[9,10,17,21]. In our previous works[3–5], we reclassified patients who are clinically diagnosed as T2D into two subgroups, representing the classical and atypical cases, as described in the Materials and Methods section. Intriguingly, these previous studies consistently found that the two case categories were different at the genetic level, involving several genes. In the current study, we amplified the genetic characterization of atypical diabetes in Uruguayans to include the analysis of two SNPs strongly related with T2D according to other populations studied and reported.

Analyzing the T2D study population in comparison to the control population showed us a significant association of the rs12255372 SNP. The same results have been found in other studies of different populations, and the presence of the T allele was also found to be associated to major proneness to T2D[21,31,32]. Subsequent analysis of our results from the T2D patients upon subgrouping according to atypical and classical cases, and in comparison with controls, showed an increase in OR when we removed the atypical patients from the analysis for rs12255372. This finding could indicate that the atypical subpopulation of T2D patients could serve as a confounding factor in general analyses of T2D patients, highlighting the potential of the overall T2D population being a mixture of case subgroups. This subgroup profile may help to explain previous results observed in different studies that used the T2D pooled population as a unique group.

The ideas expressed above are in accordance with the notion that atypical patients could be framed as a separated group from patients with classical T2D[3]. Another perspective sets atypical diabetes in a mid-course status between type 1 diabetes and T2D, as described by Pozzilli *et al*[33]; as such, the atypical diabetes case would be located in the middle of the T2D disease spectrum. This concept goes along with the so-called “accelerator hypothesis”, which states that -cell loss could be variably accelerated by the conjunction and different weight of three different processes: insulin resistance, autoimmunity and constitution[34,35]. The -cells of those individuals carrying the *TCF7L2* gene mutations are more susceptible than others to the metabolic demands of insulin resistance[36], but not as susceptible as those carrying the HLA DR3/DR4 haplotype, as in the case of the atypical diabetes population, providing a combination of unfavorable genetic background, impairment in -cell secretion and a diminished survival upon challenge with hyperglycemic stress, as well as establishing an autoimmune cell environment[14,26,37].

Interestingly, the rs7903146 SNP did not show significant association with T2D in our analyses. The Uruguayan population has a three-hybrid admixed origin⎯European, African and Amerindian; the Caucasian component represents a major proportion, but there is a significant mixegenation degree and a noteworthy Amerindian component of maternal origin[38]. Studies performed in different Asian populations[39–42] have found no significant association between this SNP of the *TCF7L2* gene and T2D. Thus, one could ponder the idea that the Uruguayan population may be more related to Asian populations than expected; this idea might also be supported by the theory that the American continent was populated by Asian ancestors[38].

Beyond the ethnic influence that has also been found in other studies of rs12255372 and rs7903146[17–25], this study showed that the association of rs12255372 with diabetes was increased when the population was reclassified as subgroups of case types and only the classical T2D patients were compared with controls. This finding suggests the importance of taking into consideration the existence of an atypical group, which could serve to obscure the real association of SNPs in the *TCF7L2* gene. On the other hand, it is important to note that studies using populations of patients with LADA have found differences in the polymorphisms of the *TCF7L2* gene as well as with T2D[43,44]. This finding reinforces the theory that LADA and atypical diabetes are distinct entities.

To continue the characterization of the atypical diabetes subpopulation it will be important to obtain measurements of C-peptide from the patients, so as to study if there is any difference for this marker between the subpopulations classified. The C-peptide is a precursor of insulin whose measurement shows the reserve of secretion of the same by the pancreatic -cell. It is very useful in those patients with poor response to antihyperglycemic medication, as is the case of our atypical patients. Therefore, this technique would represent another resource to help in the classification and a more appropriate therapeutic in this population of complex patients.

Today, in our country, the investigation of C-peptide is not routinely performed and is only carried out in some specialized centers. Therefore, it becomes of paramount importance to implement the C-peptide measurement in the Healthcare Centers and Hospitals in our country. In addition, it will be important to continue characterizing the atypical diabetes subpopulation through the study of genetic markers. Identification and characterization of disease-specific genetic markers will help doctors to more readily and more accurately classify these cases, according to an etiopathogenic base. Such could also lead us to designing and implementing a therapy that will avoid or minimize trial and error time.

At the same time, therapeutic inertia would facilitate advancement of the chronic complications of this pathology. In the group of patients investigated in this study, we took into account the presence of clinical biomarkers. Although we cannot speak from a statistical point of view (due to the short time elapsed during the study period), we have managed to individualize the therapy (data not shown). In turn, this has led our patients with atypical presentation to have greater confidence in the treatment used, such as the acceptance of a timely insulinization.

Ultimately, this study showed that the application of a translational medicine research approach provides knowledge of basic science that can be applied directly in the clinic towards the resolution of complex clinical cases.

We have studied two of the most relevant SNP variants related to T2D, in the *TCF7L2* gene, in a Uruguayan diabetic population stratified by genotype differences. The present and previous works support the idea that the combined effect of several predisposition variants would turn the atypical subpopulation into a new classification and serve as therapeutic targets[45].

Currently, there are different classifications that encompass atypical patients, placing them within different categories. Stenkamp *et al*[46] refer to a group of patients who would meet some of the criteria described herein as diabetic (ketosis-prone diabetes), while other authors locate these patients within a subset of the LADA patients[47]. Overall, this reaffirms the necessity to continue the genetic analysis of this particular population to achieve a more adequate classification and treatment of these patients.

**ARTICLE HIGHLIGHTS**

***Research background***

In a high percentage of patients, clinical presentation alone does not define the type of diabetes. This is very important, since it hinders implementation of an individualized and safe treatment. The current classification system of diabetes is useful and easy for typical patients. However, there are many situations in which it is difficult to determine what type of diabetes is presenting due to the great heterogeneity in the pathogenesis. The current classification of diabetes is not satisfactory and its revision has been under consideration for many years. Previous studies carried out in the Uruguayan population have demonstrated the existence of patients for who it is not possible to classify into any of the categories provided in the international guidelines. We continue to investigate this type of patient because it is very important to assist them appropriately and improve their quality of life. In this way, it is possible to abolish the trial stage and error that patients suffer from when not being correctly diagnosed. At this time, different researchers have proposed that the classifications of diabetes should be revised, and this is the principal objective of our work. We have emphatically proposed the inclusion of genetics determination for HLA to elucidate atypical diabetes patients. Such an approach and related data will permit correct classification and treatment for these kinds of patients.

***Research motivation***

To date, we have investigated genes related to type 1 diabetes in patients with atypical diabetes. In this study, we sought to analyze the major gene related to type 2 diabetes, the *TCF7L2* gene, in the atypical diabetes patients.

***Research objectives***

To analyze the association of the two most important single nucleotide polymorphisms (SNPs) of the *TCF7L2* gene-rs12255372 and rs7903146-with atypical diabetes.

***Research methods***

This case-control study was conducted in atypical and classical cases of type 2 diabetes using genotypification with *Taq*Man probes for the rs12255372 and rs7903146SNPs of the *TCF7L2* gene.

***Research results***

The SNPs of the *TCF7L2* gene that were analyzed in this work showed no association with atypical diabetes; nevertheless, the rs12255372 SNP was associated with classical diabetes.

***Research conclusions***

As has been shown in previous studies, the genetics of atypical diabetes are different from those of classical diabetes, despite a shared phenotype.

***Research perspectives***

To continue the characterization of the atypical diabetes subpopulation it will be important to obtain measurements of C-peptide in these patients and to study if there is any difference for this marker between the populations classified.

**ACKNOWLEDGMENTS**

The authors would like to express their gratitude to the personnel of the Hemotherapy Department at the Pasteur Hospital, Montevideo, Uruguay.

**REFERENCES**

1 **Ferrero R,** García MV. Encuesta de prevalencia de la diabetes en Uruguay. *Arch Med Interna* 2005; **27**: 7–12

2 **Instituto Nacional de Estadística.** Censos 2011 – contame que te cuento. Available from: URL: http://www5.ine.gub.uy/censos2011/index.html

3 **Mimbacas A**, García L, Zorrilla P, Acosta M, Airaudo C, Ferrero R, Pena A, Simonelli B, Soto E, Vitarella G, Fernandez J, Javiel G. Genotype and phenotype correlations in diabetic patients in Uruguay. *Genet Mol Res* 2009; **8**: 1352-1358 [PMID: 19937591 DOI: 10.4238/vol8-4gmr667]

4 **Fernández M**, Fabregat M, Javiel G, Mimbacas A. HLA alleles may serve as a tool to discriminate atypical type 2 diabetic patients. *World J Diabetes* 2014; **5**: 711-716 [PMID: 25317248 DOI: 10.4239/wjd.v5.i5.711]

5 **Fabregat M**, Fernandez M, Javiel G, Vitarella G, Mimbacas A. The Genetic Profile from HLA and Non-HLA Loci Allows Identification of Atypical Type 2 Diabetes Patients. *J Diabetes Res* 2015; **2015**: 485132 [PMID: 26273670 DOI: 10.1155/2015/485132]

6 **American Diabetes Association.** Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2014; **37** Suppl 1: S81-S90 [PMID: 24357215 DOI: 10.2337/dc14-S081]

7 **Fourlanos S**, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC. Latent autoimmune diabetes in adults (LADA) should be less latent. *Diabetologia* 2005; **48**: 2206-2212 [PMID: 16193284 DOI: 10.1007/s00125-005-1960-7]

8 **Sanghera DK**, Nath SK, Ortega L, Gambarelli M, Kim-Howard X, Singh JR, Ralhan SK, Wander GS, Mehra NK, Mulvihill JJ, Kamboh MI. TCF7L2 polymorphisms are associated with type 2 diabetes in Khatri Sikhs from North India: genetic variation affects lipid levels. *Ann Hum Genet* 2008; **72**: 499-509 [PMID: 18397358 DOI: 10.1111/j.1469-1809.2008.00443.x]

9 **Peng S**, Zhu Y, Lü B, Xu F, Li X, Lai M. TCF7L2 gene polymorphisms and type 2 diabetes risk: a comprehensive and updated meta-analysis involving 121,174 subjects. *Mutagenesis* 2013; **28**: 25-37 [PMID: 23188737 DOI: 10.1093/mutage/ges048]

10 **Qiao H**, Zhang X, Zhao X, Zhao Y, Xu L, Sun H, Fu S. Genetic variants of TCF7L2 are associated with type 2 diabetes in a northeastern Chinese population. *Gene* 2012; **495**: 115-119 [PMID: 22245614 DOI: 10.1016/j.gene.2011.12.055]

11 **Shu L**, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. *Hum Mol Genet* 2009; **18**: 2388-2399 [PMID: 19386626 DOI: 10.1093/hmg/ddp178]

12 **Polakis P**. Wnt signaling in cancer. *Cold Spring Harb Perspect Biol* 2012; **4**: [PMID: 22438566 DOI: 10.1101/cshperspect.a008052]

13 **Alami FM**, Ahmadi M, Bazrafshan H, Tabarraei A, Khosravi A, Tabatabaiefar MA, Samaei NM. Association of the TCF7L2 rs12255372 (G/T) variant with type 2 diabetes mellitus in an Iranian population. *Genet Mol Biol* 2012; **35**: 413-417 [PMID: 22888288 DOI: 10.1590/S1415-47572012005000029]

14 **Pearson ER**. Translating TCF7L2: from gene to function. *Diabetologia* 2009; **52**: 1227-1230 [PMID: 19387612 DOI: 10.1007/s00125-009-1356-1]

15 **Villareal DT**, Robertson H, Bell GI, Patterson BW, Tran H, Wice B, Polonsky KS. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. *Diabetes* 2010; **59**: 479-485 [PMID: 19934000 DOI: 10.2337/db09-1169]

16 **Ali O**. Genetics of type 2 diabetes. *World J Diabetes* 2013; **4**: 114-123 [PMID: 23961321 DOI: 10.4239/wjd.v4.i4.114]

17 **Jia HY**, Li QZ, Lv LF. Association between transcription factor 7-like 2 genetic polymorphisms and development of type 2 diabetes in a Chinese population. *Genet Mol Res* 2016; **15** [PMID: 27323175 DOI: 10.4238/gmr.15028223]

18 **Liu XH**, Xie CG, An Y, Zhang XX, Wu WB. Meta-analysis of the association between the rs7903146 polymorphism at the TCF7L2 locus and type 2 diabetes mellitus susceptibility. *Genet Mol Res* 2015; **14**: 16856-16862 [PMID: 26681031 DOI: 10.4238/2015.December.14.12]

19 **Assmann TS**, Duarte GC, Rheinheimer J, Cruz LA, Canani LH, Crispim D. The TCF7L2 rs7903146 (C/T) polymorphism is associated with risk to type 2 diabetes mellitus in Southern-Brazil. *Arq Bras Endocrinol Metabol* 2014; **58**: 918-925 [PMID: 25627047 DOI: 10.1590/0004-2730000003510]

20 **Carrasco Espí P,** Rico Sanz J, Ortega Azorín C, González Arráez JI, Ruiz de la Fuente S, Asensio Márquez EM, Estruch Riba R, Corella Piquer D. Consistente asociación del polimorfismo rs7903146 en el gen TCF7L2 con mayor riesgo de diabetes en población mediterránea española. *Clínica e Investig en Arterioscler* 2011; **23**: 125–32 [DOI: 10.1016/j.arteri.2011.04.002]

21 **Wang J**, Zhang J, Li L, Wang Y, Wang Q, Zhai Y, You H, Hu D. Association of rs12255372 in the TCF7L2 gene with type 2 diabetes mellitus: a meta-analysis. *Braz J Med Biol Res* 2013; **46**: 382-393 [PMID: 23579632 DOI: 10.1590/1414-431X20132677]

22 **Luo Y**, Wang H, Han X, Ren Q, Wang F, Zhang X, Sun X, Zhou X, Ji L. Meta-analysis of the association between SNPs in TCF7L2 and type 2 diabetes in East Asian population. *Diabetes Res Clin Pract* 2009; **85**: 139-146 [PMID: 19482368 DOI: 10.1016/j.diabres.2009.04.024]

23 **Tong Y**, Lin Y, Zhang Y, Yang J, Zhang Y, Liu H, Zhang B. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. *BMC Med Genet* 2009; **10**: 15 [PMID: 19228405 DOI: 10.1186/1471-2350-10-15]

24 **Bodhini D**, Radha V, Dhar M, Narayani N, Mohan V. The rs12255372(G/T) and rs7903146(C/T) polymorphisms of the TCF7L2 gene are associated with type 2 diabetes mellitus in Asian Indians. *Metabolism* 2007; **56**: 1174-1178 [PMID: 17697858 DOI: 10.1016/j.metabol.2007.04.012]

25 **Cauchi S**, El Achhab Y, Choquet H, Dina C, Krempler F, Weitgasser R, Nejjari C, Patsch W, Chikri M, Meyre D, Froguel P. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. *J Mol Med* (Berl) 2007; **85**: 777-782 [PMID: 17476472 DOI: 10.1007/s00109-007-0203-4]

26 **Pang DX**, Smith AJ, Humphries SE. Functional analysis of TCF7L2 genetic variants associated with type 2 diabetes. *Nutr Metab Cardiovasc Dis* 2013; **23**: 550-556 [PMID: 22402060 DOI: 10.1016/j.numecd.2011.12.012]

27 **Saxena R**, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjögren M, Florez JC, Almgren P, Isomaa B, Orho-Melander M, Lindblad U, Daly MJ, Tuomi T, Hirschhorn JN, Ardlie KG, Groop LC, Altshuler D. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. *Diabetes* 2006; **55**: 2890-2895 [PMID: 17003358 DOI: 10.2337/db06-0381]

28 **Pilgaard K**, Jensen CB, Schou JH, Lyssenko V, Wegner L, Brøns C, Vilsbøll T, Hansen T, Madsbad S, Holst JJ, Vølund A, Poulsen P, Groop L, Pedersen O, Vaag AA. The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. *Diabetologia* 2009; **52**: 1298-1307 [PMID: 19288077 DOI: 10.1007/s00125-009-1307-x]

29 **Nathan DM**, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009; **32**: 193-203 [PMID: 18945920 DOI: 10.2337/dc08-9025]

30 **Mimbacas A**, Pérez-Bravo F, Santos JL, Pisciottano C, Grignola R, Javiel G, Jorge AM, Cardoso H. The association between HLA DQ genetic polymorphism and type 1 diabetes in a case-parent study conducted in an admixed population. *Eur J Epidemiol* 2004; **19**: 931-934 [PMID: 15575351 DOI: 10.1007/s10654-004-5176-9]

31 **González-Sánchez JL**, Martínez-Larrad MT, Zabena C, Pérez-Barba M, Serrano-Ríos M. Association of variants of the TCF7L2 gene with increases in the risk of type 2 diabetes and the proinsulin:insulin ratio in the Spanish population. *Diabetologia* 2008; **51**: 1993-1997 [PMID: 18712344 DOI: 10.1007/s00125-008-1129-2]

32 **Ciccacci C**, Di Fusco D, Cacciotti L, Morganti R, D'Amato C, Novelli G, Sangiuolo F, Spallone V, Borgiani P. TCF7L2 gene polymorphisms and type 2 diabetes: association with diabetic retinopathy and cardiovascular autonomic neuropathy. *Acta Diabetol* 2013; **50**: 789-799 [PMID: 22843023 DOI: 10.1007/s00592-012-0418-x]

33 **Pozzilli P**, Buzzetti R. A new expression of diabetes: double diabetes. *Trends Endocrinol Metab* 2007; **18**: 52-57 [PMID: 17208448 DOI: 10.1016/j.tem.2006.12.003]

34 **Wilkin TJ**. The accelerator hypothesis cannot be tested using the type 2 diabetes gene, TCF7L2. *Diabetologia* 2007; **50**: 1780 [PMID: 17589824 DOI: 10.1007/s00125-007-0725-x]

35 **Wilkin TJ**. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. *Diabetologia* 2001; **44**: 914-922 [PMID: 11508279 DOI: 10.1007/s001250100548]

36 **Grant SF**, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. *Nat Genet* 2006; **38**: 320-323 [PMID: 16415884 DOI: 10.1038/ng1732]

37 **Le Bacquer O**, Shu L, Marchand M, Neve B, Paroni F, Kerr Conte J, Pattou F, Froguel P, Maedler K. TCF7L2 splice variants have distinct effects on beta-cell turnover and function. *Hum Mol Genet* 2011; **20**: 1906-1915 [PMID: 21357677 DOI: 10.1093/hmg/ddr072]

38 **Salzano FM**, Sans M. Interethnic admixture and the evolution of Latin American populations. *Genet Mol Biol* 2014; **37**: 151-170 [PMID: 24764751]

39 **Pourahmadi M**, Erfanian S, Moradzadeh M, Jahromi AS. Non-Association between rs7903146 and rs12255372 Polymorphisms in Transcription Factor 7-Like 2 Gene and Type 2 Diabetes Mellitus in Jahrom City, Iran. *Diabetes Metab J* 2015; **39**: 512-517 [PMID: 26616591 DOI: 10.4093/dmj.2015.39.6.512]

40 **Saadi H**, Nagelkerke N, Carruthers SG, Benedict S, Abdulkhalek S, Reed R, Lukic M, Nicholls MG. Association of TCF7L2 polymorphism with diabetes mellitus, metabolic syndrome, and markers of beta cell function and insulin resistance in a population-based sample of Emirati subjects. *Diabetes Res Clin Pract* 2008; **80**: 392-398 [PMID: 18282631 DOI: 10.1016/j.diabres.2008.01.008]

41 **Chang YC**, Chang TJ, Jiang YD, Kuo SS, Lee KC, Chiu KC, Chuang LM. Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. *Diabetes* 2007; **56**: 2631-2637 [PMID: 17579206 DOI: 10.2337/db07-0421]

42 **Guo T**, Hanson RL, Traurig M, Muller YL, Ma L, Mack J, Kobes S, Knowler WC, Bogardus C, Baier LJ. TCF7L2 is not a major susceptibility gene for type 2 diabetes in Pima Indians: analysis of 3,501 individuals. *Diabetes* 2007; **56**: 3082-3088 [PMID: 17909099 DOI: 10.2337/db07-0621]

43 **Zampetti S**, Spoletini M, Petrone A, Capizzi M, Arpi ML, Tiberti C, Di Pietro S, Bosi E, Pozzilli P, Giorgino F, Buzzetti R; Nirad Study Group. Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD Study 5). *Diabet Med* 2010; **27**: 701-704 [PMID: 20546291 DOI: 10.1111/j.1464-5491.2010.02997.x]

44 **Szepietowska B**, Moczulski D, Wawrusiewicz-Kurylonek N, Grzeszczak W, Gorska M, Szelachowska M. Transcription factor 7-like 2-gene polymorphism is related to fasting C peptide in latent autoimmune diabetes in adults (LADA). *Acta Diabetol* 2010; **47**: 83-86 [PMID: 19533015 DOI: 10.1007/s00592-009-0133-4]

45 **Schwartz SS**, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. *Diabetes Care* 2016; **39**: 179-186 [PMID: 26798148 DOI: 10.2337/dc15-1585]

46 **Steenkamp DW**, Alexanian SM, Sternthal E. Approach to the patient with atypical diabetes. *CMAJ* 2014; **186**: 678-684 [PMID: 24396100 DOI: 10.1503/cmaj.130185]

47 **Manuel García de los Ríos A,** Pilar Durruty A, editors. Diabetes Mellitus, 3ed. Rethymno: Mediterráneo, 2013

**P-Reviewer:** Beltowski j, Hasan m, Hssan MMA, Kusmic C **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Specialty type:** Genetics and Heredity

**Country of origin:** Uruguay

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): C, C, C, C

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Anthropometric characteristics of the study population**

|  |  |  |
| --- | --- | --- |
|  | **Healthy controls** | **Type 2 diabetes cases** |
| *n* | 133 | 177 |
| Male/Female | 76/57 | 87/90 |
| Age (yr) | 37.49 ± 13.04 | 63.05 ± 11.66 |
| BMI (kg/m2) | 25.17 ± 5.35 | 31.73 ± 5.65 |

BMI: Body mass index; SD: Standard deviation.

**Table 2 Clinical characteristics of the atypical and classical diabetes cases**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Atypical diabetes, *n* = 92** | **Classical diabetes, *n* = 85** | ***P*** |
|  |
| Age (yr) | 61.29 ± 13.08 | 65.74 ± 9.93 | 0.011b |
| Age ( yr) | 43.36 ± 12.62 | 45.93 ± 14.67 | 0.304 |
| BMI (kg/m2) | 32.22 ± 5.48 | 31.32 ± 5.96 | 0.288 |
| HbA1c, % | 8.27 ± 1.80 | 8.27 ± 1.77 | 0.993 |
| Total cholesterol (mmol/L) | 5.18 ± 1.14 | 5.53 ± 1.16 | 0.044a |
| HDL (mmol/L) | 1.24 ± 0.29 | 1.32 ± 0.33 | 0.080 |
| LDL (mmol/L) | 2.84 ± 1.02 | 3.26 ± 1.11 | 0.010b |
| Triglycerides (mmol/L) | 2.24 ± 1.40 | 2.24 ± 1.4 | 0.991 |
| TG/HDL | 4.47 ± 3.41 | 4.43 ± 4.73 | 0.941 |

a*P* < 0.05, b*P* < 0.01, for all parameters. BMI: Body mass index; HbA1c: Glycated hemoglobin; HDL: High-density lipoprotein-cholesterol; LDL: Low-density lipoprotein-cholesterol; TG/HDL: Insulin resistance index.

**Table 3 Genotype frequencies of rs12255372 and rs7903146 in controls and cases**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **SNPs** | **Healthy controls, %** | **Type 2 diabetes cases, %** | **OR (95%CI)** | ***P*** |
|
| **rs12255372 G>T** |  |  |  |  |
| G/T+T/T | 48.9 | 60.5 | 1.6 (1.02-2.51) | 0.04 |
| G/G | 51.1 | 39.5 |
| T allele | 30 | 37 | 1.37 (0.97-1.92) | NS |
| G allele | 70 | 63 |
| **rs7903146 C>T** |  |  |  |  |
| C/T+T/T | 46.6 | 52.5 | 1.27 (0.81-1.99) | NS |
| C/C | 53.4 | 47.5 |
| T allele | 29 | 34 | 1.22 (0.87-1.72) | NS |
| C allele | 71 | 66 |

CI: Confidence interval; NS: Non-significant; OR: Odds ratio; SNP: Single nucleotide polymorphism.

**Table 4 Genotype frequencies of rs12255372 and rs7903146 in controls, atypical diabetes and classical diabetes patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SNPs** | **Controls, %** | **Atypical diabetes, %** | **Classical diabetes, %** | **OR (95%CI)** | ***P*** |
|
| **rs12255372 G>T** |  |  |  |  |  |
| G/T+T/T | 65 | **-** | 57 | 2.1 (1.21-3.75) | 0.008 |
| G/G | 68 | **-** | 28 |
| G/T+T/T | 65 | 50 | **-** | 1.2 (0.73-2.12) | NS |
| G/G | 68 | 42 | **-** |
| **rs7903146 C>T** |  |  |  |  |  |
| C/T+T/T | 62 | **-** | 47 | 1.4 (0.82-2.45) | NS |
| C/C | 71 | **-** | 38 |
| C/T+T/T | 62 | 46 | **-** | 1.2 (0.67-1.95) | NS |
| C/C | 71 | 46 | **-** |

SNP: Single nucleotide polymorphism; CI: Confidence interval; NS: Non-significant; OR: Odds ratio; SNP: Single nucleotide polymorphism.